China Exposes Four New Pharmacy Fraud Cases in Crackdown

China’s National Healthcare Security Administration (NHSA) has publicly disclosed four new cases of pharmacy insurance fraud as part of an intensifying nationwide campaign to protect the country’s medical insurance fund, which covers over 1.3 billion people. The cases, published on June 7, represent the fourth batch of typical violations uncovered through the agency’s “flying inspection” program launched on May 14, according to the NHSA.

The 2026 Anti-Fraud Campaign

The latest disclosures bring the total number of exposed cases to 18 across four batches since May 8, signaling an unprecedented intensity in enforcement. The campaign operates in two phases (April-July and September-November 2026) and leverages big data analytics and drug traceability codes to identify suspicious patterns that would be invisible to traditional audits, as reported by Xinhua News.

Previous batches targeted patients over-purchasing and reselling prescription drugs (Batch 1, May 8) and pharmacy-level violations including substitution of non-medical items for medicines (Batches 2 and 3, May 27 and May 31).

The Four New Cases

Case 1: Nighttime Data Tampering in Qinghai

In Xining, Qinghai Province, inspectors from the NHSA’s special flight inspection team found that Xinlüzhou Pharmaceutical Chain Co., Ltd. Xiangrui Pharmacy was involved in selling “returned drugs” — medications originally purchased by patients that were then resold. Big data screening identified that boxes of Felodipine Extended-Release Tablets and Metformin Hydrochloride Tablets appeared in settlement records twice at different pharmacies.

During the inspection, between 22:40 and 23:44 at night, the pharmacy suddenly added nearly 20 new prescription and drug outbound records to balance inventory data. The pharmacy manager admitted to modifying system records overnight to prepare for the inspection. The case has been referred to local medical insurance authorities for further investigation.

Case 2: One Box of Medicine Sold Twice

Also in Xining, Wanyi Pharmaceutical Chain Co., Ltd. No. 8 Pharmacy was found to have sold the same box of Felodipine Extended-Release Tablets twice — first on February 24 and again on March 26 — using pooled fund settlement on both occasions. The pharmacy could not provide purchase invoices or delivery documents for the medication. The case has been referred to local authorities.

Case 3: Jujubes Turned Into a “Profit Tool”

In Nanning, Guangxi Zhuang Autonomous Region, Guihetang Pharmacy Co., Ltd. Heping Branch operated an elaborate scheme using a “low-price purchase + high-price sale + coupon rebate” model. Inspectors discovered handwritten ledgers and QQ group chat records detailing how the pharmacy substituted non-medical items for insured drugs.

One patient spent 11,533 yuan (approximately $1,590) from January 2025 to May 2026 on items including “Buzhong Yiqi Tablets” and jujubes, while the total purchase cost was only 926.08 yuan — a markup of over 12 times. The pharmacy issued 192 coupons worth 50 yuan each (total 9,600 yuan) to the same patient for purchasing other items.

Case 4: Pharmacy Swiping Cards for Non-Designated Clinic

In Hezhou, Guangxi, Babu Guikang Pharmacy Second Branch was found to be operating in coordination with a traditional Chinese medicine clinic on the second floor, sharing the same actual controller, cash register, and computer system. Patients would swipe their medical insurance cards at the pharmacy without taking any medicine, and the amount would be deposited into a prepaid account at the clinic for massage, physiotherapy, and medication purchases. Surveillance video footage confirmed the violations.

Big Data as a Deterrent

“In the era of big data, any illegal or irregular behavior has nowhere to hide,” the NHSA stated, as reported by CCTV News. The agency warned that selling returned drugs, empty swiping, fraudulent substitution, or defrauding medical insurance funds are all violations of medical security laws and regulations.

Broader Implications

The geographic scope of the cases — spanning from Hainan in the south to Xinjiang in the northwest, Qinghai in the west to Jilin in the northeast — indicates a nationwide problem. The 2026 campaign builds on previous years’ efforts, with each year seeing more sophisticated detection methods. The use of “flying inspections” and big data analytics represents a shift from reactive to proactive enforcement.

China’s medical insurance fund faces significant pressure from an aging population and rising healthcare costs, making the protection of these resources a national priority. The NHSA maintains a whistleblower hotline and has urged the public to report suspicious activity.

What to Watch For

All four cases have been referred to local medical insurance authorities for further investigation, but specific penalties have yet to be announced. The question remains whether criminal charges will be filed in addition to administrative penalties, and what systemic reforms might result from the patterns identified in these cases. With the campaign continuing through July and resuming in September, further disclosures are expected.